Core Viewpoint - On September 25, Xiaofang Pharmaceutical experienced a decline of 5.1%, with a stock price of 33.68 CNY per share, a trading volume of 152 million CNY, a turnover rate of 8.09%, and a total market capitalization of 5.408 billion CNY [1]. Company Overview - Xiaofang Pharmaceutical Co., Ltd. is located at 777 Hongzhu Road, Fengxian District, Shanghai, and was established on August 12, 1993. The company went public on August 26, 2024. Its main business involves the research, production, and sales of external-use medications [1]. - The revenue composition of Xiaofang Pharmaceutical is as follows: digestive medications account for 51.05%, skin medications for 39.79%, ear, nose, and throat medications for 9.08%, and other supplementary products for 0.07% [1]. Shareholder Information - Among the top ten circulating shareholders of Xiaofang Pharmaceutical, one fund under Taixin Fund ranks as a significant shareholder. The Taixin Leading Strategy Mixed Fund (290002) held 256,800 shares in the second quarter, unchanged from the previous period, representing 0.64% of the circulating shares. The estimated floating loss today is approximately 464,800 CNY [2]. - The Taixin Leading Strategy Mixed Fund (290002) was established on June 28, 2004, with a current scale of 417 million CNY. Year-to-date returns are 21.85%, ranking 4285 out of 8173 in its category; the one-year return is 34.99%, ranking 4373 out of 8003; and since inception, the return is 172.88% [2]. - The fund manager of Taixin Leading Strategy Mixed Fund is Wang Boqiang, who has a cumulative tenure of 10 years and 196 days. The total asset scale under his management is 825 million CNY, with the best fund return during his tenure being 112.25% and the worst being -36.68% [2].
小方制药股价跌5.1%，泰信基金旗下1只基金位居十大流通股东，持有25.68万股浮亏损失46.48万元